Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.52
AMAG's Cash-to-Debt is ranked lower than
87% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. AMAG: 0.52 )
Ranked among companies with meaningful Cash-to-Debt only.
AMAG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: No Debt Max: No Debt
Current: 0.52
Equity-to-Asset 0.41
AMAG's Equity-to-Asset is ranked lower than
80% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMAG: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
AMAG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.83 Max: 0.99
Current: 0.41
0.33
0.99
Debt-to-Equity 0.81
AMAG's Debt-to-Equity is ranked lower than
87% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. AMAG: 0.81 )
Ranked among companies with meaningful Debt-to-Equity only.
AMAG' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.73  Med: 1.07 Max: 1.17
Current: 0.81
0.73
1.17
Interest Coverage 0.24
AMAG's Interest Coverage is ranked lower than
99% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMAG: 0.24 )
Ranked among companies with meaningful Interest Coverage only.
AMAG' s Interest Coverage Range Over the Past 10 Years
Min: 0.24  Med: No Debt Max: No Debt
Current: 0.24
Piotroski F-Score: 3
Altman Z-Score: 0.47
Beneish M-Score: -2.62
WACC vs ROIC
3.25%
4.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 2.86
AMAG's Operating Margin % is ranked higher than
75% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. AMAG: 2.86 )
Ranked among companies with meaningful Operating Margin % only.
AMAG' s Operating Margin % Range Over the Past 10 Years
Min: -4107.64  Med: -72.84 Max: 26.59
Current: 2.86
-4107.64
26.59
Net Margin % -7.58
AMAG's Net Margin % is ranked higher than
67% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. AMAG: -7.58 )
Ranked among companies with meaningful Net Margin % only.
AMAG' s Net Margin % Range Over the Past 10 Years
Min: -3696.96  Med: -71.06 Max: 109.19
Current: -7.58
-3696.96
109.19
ROE % -4.83
AMAG's ROE % is ranked higher than
73% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. AMAG: -4.83 )
Ranked among companies with meaningful ROE % only.
AMAG' s ROE % Range Over the Past 10 Years
Min: -52.39  Med: -15.27 Max: 42.96
Current: -4.83
-52.39
42.96
ROA % -1.84
AMAG's ROA % is ranked higher than
75% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. AMAG: -1.84 )
Ranked among companies with meaningful ROA % only.
AMAG' s ROA % Range Over the Past 10 Years
Min: -44.82  Med: -13.1 Max: 16.42
Current: -1.84
-44.82
16.42
ROC (Joel Greenblatt) % 44.03
AMAG's ROC (Joel Greenblatt) % is ranked higher than
95% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. AMAG: 44.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMAG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1009.91  Med: -510.9 Max: 475.79
Current: 44.03
-1009.91
475.79
3-Year Revenue Growth Rate 60.80
AMAG's 3-Year Revenue Growth Rate is ranked higher than
89% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. AMAG: 60.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMAG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -78.7  Med: 10.3 Max: 278.5
Current: 60.8
-78.7
278.5
3-Year EPS without NRI Growth Rate -45.80
AMAG's 3-Year EPS without NRI Growth Rate is ranked lower than
90% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. AMAG: -45.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMAG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51.7  Med: -8.15 Max: 100
Current: -45.8
-51.7
100
GuruFocus has detected 4 Warning Signs with AMAG Pharmaceuticals Inc $AMAG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMAG's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

AMAG Guru Trades in Q3 2016

Joel Greenblatt 507,809 sh (+23.28%)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2016

AMAG Guru Trades in Q4 2016

Jim Simons 513,500 sh (New)
Paul Tudor Jones 11,200 sh (New)
Joel Greenblatt 600,584 sh (+18.27%)
» More
Q1 2017

AMAG Guru Trades in Q1 2017

Paul Tudor Jones 22,300 sh (+99.11%)
Jim Simons 766,000 sh (+49.17%)
Joel Greenblatt 678,918 sh (+13.04%)
» More
Q2 2017

AMAG Guru Trades in Q2 2017

Joel Greenblatt 800,055 sh (+17.84%)
Jim Simons 778,800 sh (+1.67%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Add 17.84%0.03%$16.1 - $24.65 $ 18.45-7%800,055
Joel Greenblatt 2017-03-31 Add 13.04%0.02%$21.4 - $35.85 $ 18.45-23%678,918
Joel Greenblatt 2016-12-31 Add 18.27%0.04%$23.19 - $36.05 $ 18.45-38%600,584
Joel Greenblatt 2016-09-30 Add 23.28%0.03%$22.31 - $27.7 $ 18.45-26%507,809
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ABEO, NAS:BOLD, NAS:ALDR, NAS:ACRS, NAS:AKAO, NAS:LJPC, NAS:PRTK, NAS:DOVA, NAS:INSY, NAS:CHRS, NAS:GTHX, NAS:RXDX, NAS:VSAR, NAS:ANAB, NAS:MGNX, NAS:CTMX, NAS:RVNC, NAS:CYTK, NAS:IMGN, NAS:KALA » details
Traded in other countries:AMU.Germany,
Headquarter Location:USA
AMAG Pharmaceuticals Inc is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and to aid in the diagnosis of cancer.

Founded in 1981, AMAG Pharmaceuticals uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging.

Ratios

vs
industry
vs
history
Forward PE Ratio 11.57
AMAG's Forward PE Ratio is ranked higher than
95% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. AMAG: 11.57 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 5.93
AMAG's Price-to-Owner-Earnings is ranked higher than
91% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. AMAG: 5.93 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AMAG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.58  Med: 10.23 Max: 24.48
Current: 5.93
4.58
24.48
PB Ratio 0.68
AMAG's PB Ratio is ranked higher than
96% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. AMAG: 0.68 )
Ranked among companies with meaningful PB Ratio only.
AMAG' s PB Ratio Range Over the Past 10 Years
Min: 0.61  Med: 2.36 Max: 18.97
Current: 0.68
0.61
18.97
PS Ratio 1.16
AMAG's PS Ratio is ranked higher than
94% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. AMAG: 1.16 )
Ranked among companies with meaningful PS Ratio only.
AMAG' s PS Ratio Range Over the Past 10 Years
Min: 1  Med: 6.33 Max: 505.93
Current: 1.16
1
505.93
Price-to-Free-Cash-Flow 3.64
AMAG's Price-to-Free-Cash-Flow is ranked higher than
94% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. AMAG: 3.64 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AMAG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.24  Med: 12.74 Max: 1492.35
Current: 3.64
3.24
1492.35
Price-to-Operating-Cash-Flow 3.50
AMAG's Price-to-Operating-Cash-Flow is ranked higher than
94% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. AMAG: 3.50 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMAG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.15  Med: 12.57 Max: 1409.44
Current: 3.5
3.15
1409.44
EV-to-EBIT 95.23
AMAG's EV-to-EBIT is ranked lower than
61% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. AMAG: 95.23 )
Ranked among companies with meaningful EV-to-EBIT only.
AMAG' s EV-to-EBIT Range Over the Past 10 Years
Min: -787.3  Med: -5.2 Max: 101.5
Current: 95.23
-787.3
101.5
EV-to-EBITDA 7.99
AMAG's EV-to-EBITDA is ranked higher than
78% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. AMAG: 7.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMAG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -148.3  Med: -5.15 Max: 479.9
Current: 7.99
-148.3
479.9
EV-to-Revenue 1.74
AMAG's EV-to-Revenue is ranked higher than
90% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. AMAG: 1.74 )
Ranked among companies with meaningful EV-to-Revenue only.
AMAG' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.3  Med: 3.9 Max: 435.3
Current: 1.74
0.3
435.3
Current Ratio 1.51
AMAG's Current Ratio is ranked lower than
72% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. AMAG: 1.51 )
Ranked among companies with meaningful Current Ratio only.
AMAG' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 9.9 Max: 62.43
Current: 1.51
1.51
62.43
Quick Ratio 1.41
AMAG's Quick Ratio is ranked lower than
69% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. AMAG: 1.41 )
Ranked among companies with meaningful Quick Ratio only.
AMAG' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 9.42 Max: 61
Current: 1.41
1.4
61
Days Inventory 101.52
AMAG's Days Inventory is ranked higher than
57% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. AMAG: 101.52 )
Ranked among companies with meaningful Days Inventory only.
AMAG' s Days Inventory Range Over the Past 10 Years
Min: 101.52  Med: 441.37 Max: 1713.48
Current: 101.52
101.52
1713.48
Days Sales Outstanding 55.04
AMAG's Days Sales Outstanding is ranked higher than
58% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. AMAG: 55.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMAG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.4  Med: 49.36 Max: 581.14
Current: 55.04
27.4
581.14
Days Payable 21.86
AMAG's Days Payable is ranked lower than
77% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. AMAG: 21.86 )
Ranked among companies with meaningful Days Payable only.
AMAG' s Days Payable Range Over the Past 10 Years
Min: 11.5  Med: 130.3 Max: 2881.25
Current: 21.86
11.5
2881.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.40
AMAG's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. AMAG: -16.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMAG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.7  Med: -6.3 Max: 0.7
Current: -16.4
-28.7
0.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.39
AMAG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
98% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. AMAG: 0.39 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMAG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.39  Med: 5.68 Max: 96.83
Current: 0.39
0.39
96.83
Price-to-Median-PS-Value 0.18
AMAG's Price-to-Median-PS-Value is ranked higher than
92% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. AMAG: 0.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMAG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 1.59 Max: 207.88
Current: 0.18
0.18
207.88
Earnings Yield (Greenblatt) % 1.06
AMAG's Earnings Yield (Greenblatt) % is ranked higher than
84% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. AMAG: 1.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMAG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -458.4  Med: -6.45 Max: 6.6
Current: 1.06
-458.4
6.6

More Statistics

Revenue (TTM) (Mil) $593.24
EPS (TTM) $ -1.33
Beta0.54
Short Percentage of Float35.74%
52-Week Range $16.00 - 36.83
Shares Outstanding (Mil)35.29

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 639 561 559 621
EPS ($) 4.80 1.63 1.91 2.88
EPS without NRI ($) 4.80 1.63 1.91 2.88
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AMAG

Headlines

Articles On GuruFocus.com
AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development Sep 07 2017 
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences Sep 05 2017 
AMAG Announces U.S. FDA Filing Acceptance and Six-Month Review of Feraheme® (ferumoxytol) for the Aug 31 2017 
AMAG Completes Feraheme® (ferumoxytol) FDA Submission for the Treatment of All Adult Patients Wit Aug 03 2017 
AMAG Pharmaceuticals Launches Intrarosa™ (prasterone) in the U.S. – a Novel Product to Tre Jul 24 2017 
AMAG Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Th Jul 20 2017 
AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study Conducted by Velo Bio Jun 01 2017 
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences May 31 2017 
AMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs May 16 2017 
AMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy May 15 2017 

More From Other Websites
ETFs with exposure to AMAG Pharmaceuticals, Inc. : September 7, 2017 Sep 07 2017
AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development Sep 07 2017
AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 Sep 05 2017
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences Sep 05 2017
AMAG Pharmaceuticals (AMAG) Down 6.6% Since Earnings Report: Can It Rebound? Sep 05 2017
AMAG's Filing for Feraheme's Label Expansion Accepted by FDA Sep 01 2017
AMAG Announces U.S. FDA Filing Acceptance and Six-Month Review of Feraheme® (ferumoxytol) for the... Aug 31 2017
Edited Transcript of AMAG earnings conference call or presentation 3-Aug-17 12:00pm GMT Aug 29 2017
AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : August... Aug 10 2017
AMAG Pharmaceuticals Appoints Oscar Sanchez as Vice President of Quality Aug 08 2017
AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2 Aug 04 2017
AMAG Pharmaceuticals reports 2Q loss Aug 04 2017
AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update Aug 03 2017
AMAG Completes Feraheme® (ferumoxytol) FDA Submission for the Treatment of All Adult Patients With... Aug 03 2017
Investor Network: AMAG Pharmaceuticals, Inc. to Host Earnings Call Aug 03 2017
Spark Therapeutics (ONCE) Worth a Look: Stock Gains 5.7% Jul 24 2017
AMAG Pharmaceuticals Launches Intrarosa™ (prasterone) in the U.S. – a Novel Product to Treat... Jul 24 2017
AMAG Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference Call and Webcast on... Jul 20 2017
AMAG Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMAG) : July 5, 2017 Jul 05 2017
AMAG Pharmaceuticals Focuses on Product Development & Buyouts Jul 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}